ADCYAP1 and migraine disorder: In migraine therapeutics development, there has not yet been a false‐positive phase 2 study, so it is hopeful that PACAP‐targeted therapies will be the next big advance in migraine therapeutics, offering some mechanisms distinct from CGRP to help those underserved by these therapies.